These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35534287)

  • 1. Efficacy and Safety of Single Inhaler Triple Therapy Versus Separate Triple Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis.
    Zhang L; Wang X; Zhang Y; Chen W
    Clin Ther; 2022 Jun; 44(6):859-873. PubMed ID: 35534287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.
    Zayed Y; Barbarawi M; Kheiri B; Haykal T; Chahine A; Rashdan L; Hamid K; Sundus S; Banifadel M; Aburahma A; Bachuwa G; Chandran A
    Clin Respir J; 2019 Jul; 13(7):413-428. PubMed ID: 30947394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C; Chong J; Poole P
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.
    Long H; Xu H; Janssens JP; Guo Y
    Respir Res; 2021 Jul; 22(1):209. PubMed ID: 34301267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
    Lipson DA; Barnacle H; Birk R; Brealey N; Locantore N; Lomas DA; Ludwig-Sengpiel A; Mohindra R; Tabberer M; Zhu CQ; Pascoe SJ
    Am J Respir Crit Care Med; 2017 Aug; 196(4):438-446. PubMed ID: 28375647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
    Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple therapy for COPD: a crude analysis from a systematic review of the evidence.
    Lopez-Campos JL; Carrasco-Hernandez L; Quintana-Gallego E; Calero-Acuña C; Márquez-Martín E; Ortega-Ruiz F; Soriano JB
    Ther Adv Respir Dis; 2019; 13():1753466619885522. PubMed ID: 31694491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
    Luo J; Wang K; Liu D; Liang BM; Liu CT
    Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to single inhaler triple therapy and digital inhalers in Chronic Obstructive Pulmonary Disease: a literature review and protocol for a randomized controlled trial (TRICOLON study).
    Cuperus LJA; van der Palen J; Aldenkamp A; van Huisstede A; Bischoff EWMA; van Boven JFM; Brijker F; Dik S; van Excel JAJM; Goosens M; van Hal PTW; Kuijvenhoven JC; Kunz LIZ; Vasbinder EC; Kerstjens HAM; In 't Veen JCCM;
    BMC Pulm Med; 2024 Jul; 24(1):317. PubMed ID: 38965541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
    Cheyne L; Irvin-Sellers MJ; White J
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009552. PubMed ID: 24043433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices.
    Ram FS; Carvallho CR; White J
    Int J Chron Obstruct Pulmon Dis; 2011; 6():129-39. PubMed ID: 21468167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
    Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
    Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
    Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.